

Research Administration



Issue #36

Parker Hughes Institute

January 2002

Grant Deadlines

January 2nd

[NIH's AIDS-Related Grants Due](#)

January 22nd

[American Heart Association's Grants Due](#)

February 1st


[NIH's New \(Non-AIDS Related\) Grants Due](#)

Current Grants/Contracts

- 98011: Mast Cells in Innate Immunity Against Bacterial Infection;
P.I. Ravi Malaviya
- 98016: Pokeweed Antiviral Protein as an Universal Virus Neutralizer;
P.I. Fatih Uckun
- 99011: Roles of Cdc25 & 14-3-3 Proteins in Cell Cycle Arrest at G2/M;
P.I. Katayoon Hojjati-Emami

Table of Contents


- [Page 2:](#) NIH Guide Summary for December
- [Page 3:](#) Question of the Month
- [Page 4:](#) Changes in Grantee/Contractor Reporting of Intellectual Property Utilization
- [Page 4:](#) Website to Visit



Office of Research Administration
2699 Patton Road

David: 796-5445
Amy: 796-5401

FAX: 796-5480



NIH Guide Clipboard December Summaries



Click on the announcement for more information



NOTICES:

[Findings of Scientific Misconduct](#)

[Applications Directed to National Cancer Institute](#)

[Insulating Biomaterials](#)

[Findings of Scientific Misconduct](#)

[Changes in Grantee/Contractor Reporting of Intellectual Property Utilization](#)

[Findings of Scientific Misconduct](#)

[Novel Technologies for Noninvasive Detection, Diagnosis and Treatment of Cancer](#)

[Rapid Access to Intervention Development \(RAID\)](#)

[Development of Dosage Forms and Delivery Systems for Antitumor Agents](#)

[Early Clinical Trials of Imaging Agents](#)

REQUEST FOR APPLICATIONS:

[Rapid Response Grant Program on Bioterrorism-Related Research \(RRGP-BTRR\)](#)

[Botanical/Drug Interactions in HIV](#)

[Mathematical Models of Cytokine/Chemokine Networks in HIV Associated Lung Disease](#)

[Innovative Concepts and Approaches to Developing Functional Tissues and Organs for Heart, Vascular, Lung, and Blood Applications: Exploratory/Developmental \(R21\) Research Grants](#)



**For more information:
Please contact the Office of
Research Administration at:
796-5445 or 796-5401.**

PROGRAM ANNOUNCEMENTS:

[Partnerships for Novel Therapeutic, Diagnostic and Vector Control Strategies in Infectious Diseases](#)

[Exploratory/Developmental Grants: Technology Applications to NIAID-Funded Research](#)

[NIAID Investigator-Initiated Small Research \(R03\) Grants](#)

[Developmental /Pilot Projects in Cancer Complementary and Alternative Medicine \(CAM\)](#)

PRE-SOLICITATION ANNOUNCEMENTS:

[Cancer Prevention Fellowship Program](#)

[Cancer Prevention Research Program](#)

[Broad Agency Announcement for Novel Technologies for Noninvasive Detection, Diagnosis and Treatment of Cancer](#)

[Development of Dosage Forms and Delivery Systems for Antitumor Agents \(Amendment\)](#)

PRE-SOLICITATION ANNOUNCEMENTS Continued:

[Department of Defense \(DOD\) Small Business Technology Transfer \(STTR\) Program](#)

[Clinical Investigation Grants Program](#)

[Enzyme Linked Immunoassays of Soluble Receptors and Infused Monoclonal Antibodies](#)

[Defining and Validating Biomarkers of Risk for Progressive Cervical Cancer](#)

[Phase II Clinical Studies of New Chemopreventive Agents](#)


[CGMP Production of Vaccinia Constructs](#)

Question of the Month



For what disease is a vaccine currently mandatory for all personnel on active duty?

A prize will be awarded to the first scientist who e-mails the correct answer to this question to atang@ih.org. Good luck!



Changes in Grantee/Contractor Reporting of Intellectual Property Utilization

The Bayh-Dole Act of 1980 (P.L. 96-517) mandates grantees to report any inventions that are derived or first reduced to practice through any federal funding agreement (grant, cooperative agreement, or contract). Part of the requirements for NIH grantees includes annual reporting on the utilization of each federally funded invention.

Effective January 1, 2002, invention utilization reporting requirements will change. The most substantive change involves the addition of a question that requires the commercial name of any FDA-approved products, utilizing any invention, that have reached the market during the annual reporting period. The reporting procedure and the new list of utilization questions can be found online at the URL listed below.

For a more comprehensive explanation, refer to the web page located at:

<http://grants.nih.gov/grants/guide/notice-files/NOT-0D-02-019.html>

or contact the Office of Research Administration at 697-9228 ext. 677/688.

Website to Visit



The National Cancer Institute has issued new guidelines, separate from NIH's guidelines, regarding applications submitted via the United States Postal Service and courier services (e.g. Federal Express, DHL). These guidelines can be found at:

<http://grants.nih.gov/grants/guide/notice-files/NOT-CA-02-002.html>